Correction: Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance

Chao Shang; Lin Sun; Jiale Zhang; Bochao Zhao; Xiuxiu Chen; Huimian Xu; Baojun Huang

doi:10.18632/oncotarget.27523

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance

PDF | How to cite

Oncotarget. 2022; 13:684-685. https://doi.org/10.18632/oncotarget.27523

Metrics: PDF 676 views | ?

Chao Shang^1,2, Lin Sun³, Jiale Zhang², Bochao Zhao², Xiuxiu Chen², Huimian Xu² and Baojun Huang²

¹Department of Neurobiology, College of Basic Medicine, China Medical University, Shenyang 110001, China
²Department of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang 110004, China
³Department of Gastrointestinal Surgery, Dalian Municipal Central Hospital, Dalian 116033, China

Published: May 11, 2022

Copyright: © 2022 Shang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during image selection, incorrect images were chosen for the BCG823/BA - Control, BCG823/BA - pS-CASC9, and SGC7901/PA - Control representations in Figure 2E. The corrected Figure 2E, obtained using original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:15393–15398. DOI: https://doi.org/10.18632/oncotarget.14871

Figure 2: Knockdown of CASC9 inhibited proliferation and invasion. (A) Expression level of CASC9 in BGC823/DR and SGC7901/DR cells after transfection of pS-CASC9. (B) Growth curve of BGC823/DR cells after CASC9 knockdown. (C) Growth curve of SGC7901/DR cells after CASC9 knockdown. (D) Apoptosis of BGC823/DR and SGC7901/DR cells after CASC9 knockdown. (E) Invasion assay by transwell analysis of BGC823/DR and SGC7901/DR cells after CASC9 knockdown. (F) CASC9 knockdown decreased the numbers of trans-membrance BGC823/DR and SGC7901/DR cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27523

Publication Alerts

Corrections:

Correction: Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance